Special Issue "Advances in Peripheral Neuropathy: Clinical Symptoms, Risk Factors, Diagnosis, and Treatment"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: 31 May 2023 | Viewed by 2207

Special Issue Editors

UOC Neuroriabilitazione ad Alta Intensità, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Interests: brain injury; tDCS; virtual reality; rehabilitation; motor imagery
Special Issues, Collections and Topics in MDPI journals
UOC Neuroriabilitazione ad Alta Intensità, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Interests: peripheral neuropathy; ultrasonography; rehabilitation; electromyography; brain iniury
UOS Riabilitazione Post-Acuzie, Department of Aging, Neurological, Orthopaedic and Head-Neck Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
Interests: aging; internal medicine; geriatrics; rehabilitation; physical medicine; personalized medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Peripheral neuropathies have been widely explored across several decades in the scientific literature. During the last 20 years, researchers have provided particular attention to the recognition of the different clinical conditions inherent to peripheral neuropathies, accurate methods of diagnosis, and additional data about therapeutic possibilities. Finally, a new chapter in the topic has been traced with the SARS-Cov2 infection, which renewed scientific interest. However, despite numerous efforts to date, the data obtained in the different fields of this topic do not always result as clear or comprehensive in clinical practice. We believe that it is essential to try to order these data on the topic and also with the implications in daily practice for the different clinicians involved in the care of peripheral neuropathies.

Our Special Issue in the Journal of Clinical Medicine will aim to collect studies regarding all the aspects of peripheral neuropathy (etiology, diagnosis, treatment), in order to provide evidence (clinical studies, randomized controlled trials, review, meta-analysis) applicable to clinical practice. In particular, we aim to cover the following aspects:

  • Etiology in the peripheral neuropathies;
  • Animal studies for etiological and therapeutic interaction in the peripheral neuropathies;
  • Neuropathic pain;
  • Chemotherapy-induced peripheral neuropathy;
  • Sars-Cov2-induced peripheral neuropathy;
  • Clinical phenotypes of peripheral neuropathies;
  • Diabetes and peripheral neuropathy;
  • Traumatic peripheral neuropathies;
  • New treatment for peripheral neuropathies;
  • Rehabilitation for peripheral neuropathies;
  • New applications of diagnostic methods for peripheral neuropathies;
  • Role of physical therapies for peripheral neuropathies;
  • Minimally invasive treatments for peripheral neuropathies;
  • Dietary supplements for peripheral neuropathies;
  • Integrative medicine for clinical neuropathies.

Dr. Augusto Fusco
Dr. Luca Padua
Dr. Silvia Giovannini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peripheral neuropathies
  • neuromotor rehabilitation
  • diagnostic techniques
  • dietary supplementation
  • physical therapies
  • minimally invasive treatments
  • etiology
  • neuropathic pain

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
A Prospective, Randomized, Placebo-Controlled Study Assessing the Efficacy of Chinese Herbal Medicine (Huangqi Guizhi Wuwu Decoction) in the Treatment of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy
J. Clin. Med. 2023, 12(2), 505; https://doi.org/10.3390/jcm12020505 - 07 Jan 2023
Viewed by 643
Abstract
Objective: This study aimed to evaluate the efficacy and safety of Huangqi Guizhi Wuwu decoction (HGWD), which is composed of five crude drugs (Astragali Radix, Cinnamomi Ramulus, Paeoniae Radix Alba, Zingiberis Rhizoma Recens, and Jujubae Fructus), in the treatment of albumin-bound paclitaxel (nab-PTX)-induced [...] Read more.
Objective: This study aimed to evaluate the efficacy and safety of Huangqi Guizhi Wuwu decoction (HGWD), which is composed of five crude drugs (Astragali Radix, Cinnamomi Ramulus, Paeoniae Radix Alba, Zingiberis Rhizoma Recens, and Jujubae Fructus), in the treatment of albumin-bound paclitaxel (nab-PTX)-induced peripheral neuropathy (PN) in Chinese patients with breast cancer (BC). Methods: This trial was conducted at the National Cancer Center in China from January 2020 to June 2022. The eligible participants were assigned randomly in a 1:1 ratio to an HGWD group or a control group. The outcome measure was EORTC QLQ-CIPN20 questionnaire. Results: 92 patients diagnosed with BC were enrolled and randomized to either HGWD group (n = 46) or control group (n = 46). There were no significant differences in baseline characteristics between the two groups (p > 0.05). A statistical analysis of the sensory and motor functions of the EORTC QLQ-CIPN20 scores showed that patients in the HGWD group reported a larger decrease in CIPN sensory scores than those in the control group (p < 0.001). The EORTC QLQ-CIPN20 autonomic scores showed no statistical significance between the two groups (p > 0.05). Conclusions: HGWD packs could significantly improve patients’ nab-PTX-induced PN, increase the tolerance for nab-PTX-containing chemotherapy, and further improve the quality of life of patients with BC. Full article
Show Figures

Figure 1

Article
Role of Sport Activity on Quality of Life in Charcot-Marie-Tooth 1A Patients
J. Clin. Med. 2022, 11(23), 7032; https://doi.org/10.3390/jcm11237032 - 28 Nov 2022
Viewed by 694
Abstract
The present study aims to investigate the benefits induced by physical activity/practiced sport in Charcot-Marie-Tooth 1A (CMT1A). Patients were divided into sport and no-sport groups according to their sports performance habit. Thirty-one patients were enrolled, of which 14 practiced sports and 17 did [...] Read more.
The present study aims to investigate the benefits induced by physical activity/practiced sport in Charcot-Marie-Tooth 1A (CMT1A). Patients were divided into sport and no-sport groups according to their sports performance habit. Thirty-one patients were enrolled, of which 14 practiced sports and 17 did not. Clinical assessments were administered to evaluate disability, self-esteem, depression, quality of life, and pain. Statistical analysis revealed significant differences in terms of gender in the no-sport group compared to the sport group (p = 0.04). Regarding the quality of life, physical function (p = 0.001), general health (p = 0.03), social function (p = 0.04), and mental health (p = 0.006) showed better patterns in the sport group than no-sport group. Moreover, neuropathic pain was reduced in the sport group according to the Neuropathic Pain Symptom Inventory (p = 0.001) and ID-PAIN (p = 0.03). The other administered questionnaires showed no significant differences. Our study confirms that CMT1A patients, who practice sports, with a similar severity of disability, may have a better physical quality of life while suffering less neuropathic pain than their peers who do not practice sports. Results recommend the prescription of sport in CMT1A patients. Full article
Article
Guillain–Barré Syndrome in Northern China: A Retrospective Analysis of 294 Patients from 2015 to 2020
J. Clin. Med. 2022, 11(21), 6323; https://doi.org/10.3390/jcm11216323 - 26 Oct 2022
Viewed by 480
Abstract
Objectives: Acute motor axonal neuropathy (AMAN) was first reported to be the main subtype of Guillain–Barré syndrome (GBS) in northern China in the 1990s. About 30 years has passed, and it is unknown whether the disease spectrum has changed over time in northern [...] Read more.
Objectives: Acute motor axonal neuropathy (AMAN) was first reported to be the main subtype of Guillain–Barré syndrome (GBS) in northern China in the 1990s. About 30 years has passed, and it is unknown whether the disease spectrum has changed over time in northern China. We aimed to study the epidemiological, clinical, and electrophysiological features of GBS in northern China in recent years. Methods: We retrospectively analyzed the medical records of GBS patients admitted to the Second Hospital of Hebei Medical University in northern China from 2015 to 2020. Results: A total of 294 patients with GBS were enrolled, with median age 53 years and 60.5% of participants being male, and a high incidence in summer and autumn. AMAN was still the predominant subtype in northern China (40.1%). The AMAN patients had shorter time to nadir, longer hospitalization time, and a more severe HFGS score at discharge than acute inflammatory demyelinating polyneuropathies (AIDP) (p < 0.05). With SPSS multivariable logistic regression analysis, we found the GBS disability score (at admission), dysphagia, and dysautonomia were independent risk factors for GBS patients requiring MV (p < 0.05). In comparison with other regions, the proportion of AMAN in northern China (40.1%) was higher than in eastern (35%) and southern (19%) China. Conclusions: AMAN is still the predominant subtype in northern China after 30 years, but there have been changes over time in the GBS spectrum since the 1990s. There are regional differences in GBS in China. Full article
Show Figures

Figure 1

Back to TopTop